CME Presentations

Improving Physician-Patient Decision Making for Treatment of CLL with BTK Inhibition



  • Anthony Mato, MD, MSCE

    Anthony Mato, MD, MSCE

    Anthony Mato, MD, MSCE

    Director of the Chronic Lymphocytic Leukemia (CLL) Program

    Anthony R. Mato, MD, MSCE, is an associate member at Memorial Sloan Kettering Cancer Center (MSKCC) and director of the Chronic Lymphocytic Leukemia (CLL) Program at MSKCC in New York. His research on the development of clinical and translational trials for patients with CLL focuses on novel immunotherapies and immune checkpoint inhibitors. Dr Mato’s outcomes-related research explores health indicators among CLL patients in real-world settings. A well-published scholar, he regularly contributes articles to peer-reviewed journals, including Blood and Lancet Oncology. Dr Mato is a member of various societies, including the American Society of Clinical Oncology, and is on the medical advisory board of the CLL Society, a patient-centric, physician-curated nonprofit organization.
  • Matthew Davids, MD, MMSc

    Matthew Davids, MD, MMSc

    Matthew Davids, MD, MMSc

    Associate Professor of Medicine

    Matthew S. Davids, MD, MMSC, is an attending physician in the Lymphoma Program of the Division of Hematologic Malignancies and associate director of the CLL Center at Dana-Farber Cancer Institute, as well as an assistant professor of medicine at Harvard Medical School in Boston. He has an active translational research program in chronic lymphocytic leukemia (CLL), studying Bcl-2 biology in his laboratory and leading clinical trials to evaluate a variety of novel therapeutic strategies in patients with CLL and other hematologic malignancies. Dr Davids received his medical degree from Yale School of Medicine in New Haven, Connecticut.

CME Information

Expanding Treatment Options for Patients with CLL: Community-Based Practice with BTK Inhibitors

Global Logo PQH Logo


After completing this activity, the participant should be better able to:
  • Differentiate between BTK inhibitors for the treatment of CLL
  • Discuss how to apply evidence-based strategies for treatment selection based on key consideration in the frontline and relapsed/refractory setting
  • Review emerging regimens with BTK inhibitors in the CLL treatment landscape
  • Apply evidence-based BTK inhibitor therapeutic strategies for CLL to maximize efficacy and minimize toxicity while incorporating patient education and counseling
This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC


This activity is supported by an educational grant from AstraZeneca.


This activity was released on August 14, 2020 and is valid for one year. Requests for credit must be made no later than August 14, 2021.


The educational design of this activity addresses the needs of hematologic oncologists, hematologists, oncology advanced practice providers (NPs and PAs), oncology nurses, and other clinicians involved in the management of patients with CLL.


How are you differentiating between BTK inhibitors for your patients? Patient factors such as age, IGHV status, 17p (del), del(11q), and comorbidities are all factors that should guide clinical decision-making and treatment. Dr. Matthew Davids and Dr. Anthony Mato will discuss how they differentiate between various BTK inhibitors, emerging treatment strategies involving monotherapy and combination therapies and managing treatment-related toxicities. Latest clinical data on BTK inhibitors including ibrutinib, acalabrutinib, zanubrutinib, and tirabrutinib will be presented.

Do your patients need to learn more about their CLL treatment options and why BTK inhibitors may be considered? Send patients and caregivers to to access an educational workshop as well as resources from the CLL Society. They will hear from a CLL expert, nurse practitioner, and a patient who will share their experience navigating treatment options with their team.

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity should take approximately 1 hour to complete.


In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive CE credit, participants must receive a minimum score of 70% on the post-test.


Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.


There is no fee for this educational activity.


Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Matthew S. Davids, MD, MMSc
Assistant Professor of Medicine,
Harvard Medical School;
Associate Director, Center for Chronic Lymphocytic Leukemia,
Dana-Farber Cancer Institute
Consultant/Independent Contractor: AbbVie, Adaptive Biotechnologies, AstraZeneca, BeiGene, Genentech, Janssen, MEI Pharma, Pharmacyclics, Research to Practice, Verastem, and Zentalis.
Grant/Research Support: AbbVie, Ascentage Pharma, AstraZeneca, Genentech, MEI Pharma, Pharmacyclics, Surface Oncology, TG Therapeutics, and Verastem.
Advisory Board: AbbVie, Ascentage Pharma, AstraZeneca, Celgene, Genentech, Janssen, Pharmacyclics, and TG Therapeutics.
Anthony R. Mato, MD, MSCE
Director of the Chronic Lymphocytic Leukemia (CLL) Program,
Memorial Sloan Kettering Cancer Center
Consultant/Independent Contractor: Astra Zenica, TG Therapeutics, Beigene, Pharmacyclics, Janssen, Abbvie, Genentech, LOXO, Adaptive
Grant/Research Support: Astra Zenica, TG Therapeutics, Beigene, Pharmacyclics, Janssen, Abbvie, Genentech, LOXO, Adaptive

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Tariqa Ackbarali Nothing to disclose
Elizabeth del Nido Nothing to disclose


This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Accreditation Support:
For information about the accreditation of this program, please contact Global at 303-395-1782 or

Technical Support:
For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at